Second primary malignancies in retinoblastoma patients treated with intra-arterial chemotherapy: The first 10 years Journal Article
| Authors: | Habib, L. A.; Francis, J. H.; Fabius, A. W. M.; Gobin, P. Y.; Dunkel, I. J.; Abramson, D. H. |
| Article Title: | Second primary malignancies in retinoblastoma patients treated with intra-arterial chemotherapy: The first 10 years |
| Abstract: | Background/Aims Survivors of retinoblastoma carry a lifetime risk of secondary malignancies. It is well established that external beam radiation increases this risk; however, the risk with ophthalmic artery chemosurgery (OAC) remains unknown. We report on 10 years of experience with OAC and the rate of second primary malignancy (SPM) development. Methods This is a single-centre retrospective review approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board of all patients who received OAC over a 10-year period, from May 2006 to November 2016. The second tumour incidence and survival in patients with germline disease (bilateral and unilateral with family history or confirmed germline mutation) was estimated using the Kaplan-Meier method. Patients who received external beam radiotherapy were excluded from analyses. Results Two hundred and thirty-three patients with heritable retinoblastoma who received OAC were analysed. Nineteen patients were excluded for having received external beam radiation. The Kaplan-Meier estimate of the likelihood for SPM development was 2.7% at 5 years (95% CI 0 to 25). All of the SPMs were pineoblastomas and all patients had bilateral disease in this cohort. Conclusions In our 10-year experience, we have found that SPM development in patients with germline retinoblastoma treated with OAC alone is comparable to previously published rates. In the first 10 years, OAC did not increase the known incidence of SPMs. This cohort will continue to be followed to establish the rate of development with extended follow-up. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. |
| Keywords: | cancer survival; child; preschool child; survival rate; retrospective studies; major clinical study; systemic therapy; antineoplastic agents; topotecan; follow up; follow-up studies; antineoplastic agent; carboplatin; incidence; cohort analysis; melphalan; retinoblastoma; retina tumor; retinal neoplasms; retrospective study; cancer center; infant; family history; intraarterial drug administration; infusions, intra-arterial; forecasting; electroretinography; ophthalmic artery; neoplasms, second primary; second cancer; new york; chemosurgery; pineal body tumor; trends; germline mutation; humans; human; male; female; priority journal; article |
| Journal Title: | British Journal of Ophthalmology |
| Volume: | 102 |
| Issue: | 2 |
| ISSN: | 0007-1161 |
| Publisher: | BMJ Publishing Group Ltd. |
| Date Published: | 2018-02-01 |
| Start Page: | 272 |
| End Page: | 275 |
| Language: | English |
| DOI: | 10.1136/bjophthalmol-2017-310328 |
| PUBMED: | 28600304 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 July 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work